I may be wrong but I believe that some of the additional expense might be the fee that would have been paid to Labo for acquiring exclusive distribution rights for Fillerina. The Indian company that acquired the distribution rights for their market (RPG Life Sciences) also had to pay. I remember their director mentioning that in the interview I posted about them a while ago.
Ann: Preliminary Final Report, page-7
-
- There are more pages in this discussion • 134 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
